Rhumbline Advisers Pyxis Oncology, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
A detailed history of Rhumbline Advisers transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 67,851 shares of PYXS stock, worth $71,922. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,851
Previous 64,428
5.31%
Holding current value
$71,922
Previous $236,000
55.51%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PYXS
# of Institutions
100Shares Held
24.3MCall Options Held
993KPut Options Held
42.6K-
Laurion Capital Management LP New York, NY3.63MShares$3.84 Million0.11% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.98MShares$3.16 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$2.95 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.44MShares$2.59 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.08MShares$1.15 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $37.2M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...